

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL068-098	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 04/07/2022
--	---	---	---

NAME OF PROVIDER OR SUPPLIER RSI-CLAYTON ROAD	STREET ADDRESS, CITY, STATE, ZIP CODE 417 CLAYTON ROAD CHAPEL HILL, NC 27514
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 000	<p>INITIAL COMMENTS</p> <p>An annual survey was completed on April 7, 2022. A deficiency was cited.</p> <p>This facility is licensed for the following service category: 10A NCAC 27G .5600C Supervised Living for Adults with Developmental Disabilities.</p> <p>This facility is licensed for 6 and currently has a census of 5. The survey sample consisted of audits of 3 current clients.</p>	V 000		
V 121	<p>27G .0209 (F) Medication Requirements</p> <p>10A NCAC 27G .0209 MEDICATION REQUIREMENTS (f) Medication review: (1) If the client receives psychotropic drugs, the governing body or operator shall be responsible for obtaining a review of each client's drug regimen at least every six months. The review shall be to be performed by a pharmacist or physician. The on-site manager shall assure that the client's physician is informed of the results of the review when medical intervention is indicated. (2) The findings of the drug regimen review shall be recorded in the client record along with corrective action, if applicable.</p> <p>This Rule is not met as evidenced by: Based on record reviews and interview the facility failed to obtain drug reviews every six months for two of three clients (#2 and #3) who received psychotropic drugs. The findings are: Review on 4/7/22 of Client #2's record revealed</p>	V 121		

Division of Health Service Regulation LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
--	-------	-----------

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL068-098	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 04/07/2022
--	---	---	---

NAME OF PROVIDER OR SUPPLIER RSI-CLAYTON ROAD	STREET ADDRESS, CITY, STATE, ZIP CODE 417 CLAYTON ROAD CHAPEL HILL, NC 27514
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 121	<p>Continued From page 1</p> <p>the following:</p> <ul style="list-style-type: none"> -Admission date of 8/10/81. -Diagnoses of Mild Intellectual Disabilities; Epilepsy and recurrent seizures; Cerebral Palsy. -Physician's order dated 7/30/21. <ul style="list-style-type: none"> -Divalproex Sodium 250 milligram (mg), take two tablets twice a day. -Vimpat 200 mg, Take two tablets twice a day. -The February, March and April 2022 Medication Administration Record (MAR) revealed Client #2 was administered the above medications daily. --There was no evidence of a psychotropic drug review for Client #2's medications in the last six months. Last review was conducted on 7/30/21. <p>Review on 4/7/22 of Client #3's record revealed the following:</p> <ul style="list-style-type: none"> -Admission date of 11/8/95. -Diagnoses of Generalized Anxiety Disorder; Major Depressive Disorder, recurrent; Mild Mental Retardation; Epilepsy. -Physician's order dated 7/13/21. <ul style="list-style-type: none"> -Divalproex Sodium 250 milligram (mg), take one tablet twice a day. -Levetiraceta 500 mg, take two tablets in the morning. -Levetiraceta 500 mg, take three tablets in the evening. -Primidone 250 gm, take one tablet once a day. -Risperidone 0.25 mg, take one tablet at bedtime. -Sertraline 100 mg, take two tablets once a day. -The February, March and April 2022 Medication Administration Record (MAR) revealed Client #2 was administered the above medications daily. -There was no evidence of a psychotropic drug review for Client #2's medications in the last six 	V 121		

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL068-098	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 04/07/2022
--	---	---	---

NAME OF PROVIDER OR SUPPLIER RSI-CLAYTON ROAD	STREET ADDRESS, CITY, STATE, ZIP CODE 417 CLAYTON ROAD CHAPEL HILL, NC 27514
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 121	<p>Continued From page 2</p> <p>months. Last review was conducted on 7/13/21.</p> <p>Interview on 4/7/22 with the Qualified Professional revealed: -Medication reviews for Clients #2 and #3 had been completed, but they did not receive any information from their physicians. -Staff had been trying to receive required documentation, but physician's office staff had never sent it in. -She acknowledged that the six months medication reviews for psychotropic medications for Clients #2 and #3 were not obtained.</p> <p>Interview on 4/7/22 with the Director of Autism Services revealed: -Agency relied on physicians to conduct the client 's medications reviews every six months instead of the pharmacists.</p>	V 121		